Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification

Ofelia Crombet, Kelly Lastrapes, Arthur Zieske, Jaime Morales-Arias

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

T-cell acute lymphoblastic leukemia (ALL) accounts for 15% of ALL cases in children and has been associated with a worse prognosis. Cytogenetic studies show an abnormal karyotype in 50-60% of the T-cell ALL patients; ABL1 fusions are present in approximately 8% of the cases. Dasatinib, a second-generation tyrosine kinase inhibitor, directly targets the BCR-ABL gene. We describe a pediatric case of T-cell ALL with amplification of the ABL1 gene in which remission was achieved only after the addition of dasatinib to conventional chemotherapy.

Original languageEnglish (US)
Pages (from-to)333-334
Number of pages2
JournalPediatric Blood and Cancer
Volume59
Issue number2
DOIs
StatePublished - Aug 2012

Keywords

  • ABL1 amplification
  • Acute lymphoblastic leukemia
  • Dasatinib
  • Leukemia treatment
  • T-cell ALL

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification'. Together they form a unique fingerprint.

Cite this